Illinois is currently home to 2616 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
NCT06207032
Recruiting
This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/26/2025
Locations: Southern Illinois Healthcare, Carterville, Illinois
Conditions: Cancer
Register for Updates
ICardia4HF: Multi-component MHealth Intervention for Patients with Heart Failure
NCT06205225
Recruiting
The goal of this factorial randomized trial is to examine the independent and synergistic efficacies of two mobile health technology interventions in people with chronic heart failure. The first intervention involves the use of multiple consumer mHealth apps and sensor devices (MyApps) for heart failure self-care (maintenance, monitoring, and management). The second intervention is a program of tailored text messages (Text4HF) targeting modifiable behavioral factors associated with heart failure... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Heart Failure
Register for Updates
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
NCT06163534
Recruiting
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD
NCT06075095
Recruiting
The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in participants with COPD. The study duration for each participant will be approximately 15 to 16 weeks and consist of: 1. A screening and placebo run-in period of approximately 2 weeks prior to first dosing 2. Three treatment periods of approximately 4 weeks each (one period... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
03/26/2025
Locations: Research Site, Chicago, Illinois
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763
Recruiting
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/26/2025
Locations: Rush University Medical Center- Site Number : 8400014, Chicago, Illinois
Conditions: Hemophilia A
Register for Updates
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
NCT05907096
Recruiting
The main purpose of this study is to evaluate the safety, efficacy and tolerability of ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function. The study consists of 2 parts: part A comprises the main study period, and part B comprises the long-term observational follow-up period. During part A, after the screening period, eligible participants will be randomized to receive either ARGX-117 or placebo, entering the treatment and evaluation period (duration of u... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/26/2025
Locations: University of Illinois (UI) Health - Outpatient Care Center, Chicago, Illinois
Conditions: Delayed Graft Function
Register for Updates
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
NCT05859334
Recruiting
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor cells to multiply. This may help keep tumor cells from growing and may kill them. Giving erdafitinib... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Memorial Hospital East, Shiloh, Illinois
Conditions: Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma, Recurrent Glioma
Register for Updates
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
NCT05719714
Recruiting
The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/26/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction, Kidney Diseases, Heart Failure
Register for Updates
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
NCT05531656
Recruiting
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
03/26/2025
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Early Alzheimer's Disease
Register for Updates
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT05502315
Recruiting
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer
Register for Updates
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05304767
Recruiting
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/26/2025
Locations: Local Institution - 177, Chicago, Illinois
Conditions: Schizophrenia
Register for Updates
Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study
NCT05257551
Recruiting
The study is a non-interventional evaluation of participants with SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA biomarker profiling in addition to their standard of care therapy and disease surveillance.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Illinois Cancer Care, Peoria, Illinois
Conditions: Small Cell Lung Cancer
Register for Updates